Centanafadine

From Wikipedia, the free encyclopedia

Jump to: navigation, search
Centanafadine
Centanafadine.svg
Systematic (IUPAC) name
(1R,5S)-1-naphthalen-2-yl-3-azabicyclo[3.1.0]hexane
Clinical data
Legal status
  • Investigational New Drug
Identifiers
CAS Number 924012-43-1
PubChem CID: 254741658
Chemical data
Formula C15H15N
Molecular mass 209.28 g/mol

Centanafadine (INN) (former developmental code name EB-1020) is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) under development by Neurovance in collaboration with Euthymics Bioscience as a treatment for attention deficit hyperactivity disorder (ADHD) that inhibits the reuptake of norepinephrine, dopamine and serotonin with a ratio of 1:6:14, respectively.[1][2][3] As of August 2015, it is in phase II clinical trials.[1]

See also[edit]

References[edit]

External links[edit]